hydroxyurea has been researched along with Pancreatitis in 12 studies
Pancreatitis: INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The use of hydroxyurea for the prevention of sickle cell crises in patients with homozygous HbS disease is now well established." | 9.09 | Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. ( Kalotychou, V; Loukopoulos, D; Loutradi, A; Schina, M; Theodoropoulos, I; Voskaridou, E, 2000) |
| "A new notice was distributed to health care providers cautioning of the increased risk of fatal and nonfatal pancreatitis for patients taking didanosine (Videx) from Bristol-Meyers Squibb." | 7.70 | Extended warning on Didanosine-related pancreatitis. ( , 1999) |
| "The use of hydroxyurea for the prevention of sickle cell crises in patients with homozygous HbS disease is now well established." | 5.09 | Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. ( Kalotychou, V; Loukopoulos, D; Loutradi, A; Schina, M; Theodoropoulos, I; Voskaridou, E, 2000) |
| " Incidence rates of pancreatitis were calculated for each antiretroviral regimen that included zidovudine, stavudine, didanosine (+ hydroxyurea), and didanosine + stavudine (+ hydroxyurea)." | 3.71 | Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs. ( Chaisson, RE; Keruly, JC; Moore, RD, 2001) |
| "A new notice was distributed to health care providers cautioning of the increased risk of fatal and nonfatal pancreatitis for patients taking didanosine (Videx) from Bristol-Meyers Squibb." | 3.70 | Extended warning on Didanosine-related pancreatitis. ( , 1999) |
| "Factors affecting patient adherence to therapy, such as frequent daily dosing and complex dosing schedules, are widely understood to be key obstacles to the durability of effective anti-HIV therapy." | 2.41 | Didanosine once daily: potential for expanded use. ( Pollard, RB, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 8 (66.67) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shimazu, Y | 1 |
| Fujimura, K | 1 |
| Lori, F | 1 |
| Kelly, LM | 1 |
| Foli, A | 1 |
| Lisziewicz, J | 1 |
| Reisler, RB | 1 |
| Murphy, RL | 1 |
| Redfield, RR | 1 |
| Parker, RA | 1 |
| Barie, PS | 1 |
| Tahamont, MV | 1 |
| Malik, AB | 1 |
| Pollard, RB | 1 |
| Loukopoulos, D | 1 |
| Voskaridou, E | 1 |
| Kalotychou, V | 1 |
| Schina, M | 1 |
| Loutradi, A | 1 |
| Theodoropoulos, I | 1 |
| Longhurst, HJ | 1 |
| Pinching, AJ | 1 |
| Moore, RD | 1 |
| Keruly, JC | 1 |
| Chaisson, RE | 1 |
| Havlir, DV | 1 |
| Gilbert, PB | 1 |
| Bennett, K | 1 |
| Collier, AC | 1 |
| Hirsch, MS | 1 |
| Tebas, P | 1 |
| Adams, EM | 1 |
| Wheat, LJ | 1 |
| Goodwin, D | 1 |
| Schnittman, S | 1 |
| Holohan, MK | 1 |
| Richman, DD | 1 |
| Barreiro, P | 1 |
| Soriano, V | 1 |
| Valencia, E | 1 |
| Díaz, B | 1 |
| González-Lahoz, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II Safety, Tolerability, and Pharmacokinetic Study of High Dose Lopinavir/Ritonavir With or Without Saquinavir in HIV-Infected Pediatric Subjects Previously Treated With Protease Inhibitors[NCT00084058] | Phase 1/Phase 2 | 26 participants (Actual) | Interventional | Completed | |||
| A Phase II, Randomized Study of the Safety and Efficacy of Hydroxyurea in Subjects on Potent Antiretroviral Therapy With Less Than 200 Copies/ml of HIV RNA in the Plasma[NCT00000916] | Phase 2 | 399 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for hydroxyurea and Pancreatitis
| Article | Year |
|---|---|
Safety of hydroxyurea in the treatment of HIV infection.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dose-Response Relationship, Drug; Drug Syner | 2004 |
Didanosine once daily: potential for expanded use.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; Liver; | 2000 |
4 trials available for hydroxyurea and Pancreatitis
| Article | Year |
|---|---|
Incidence of pancreatitis in HIV-1-infected individuals enrolled in 20 adult AIDS clinical trials group studies: lessons learned.
Topics: Acquired Immunodeficiency Syndrome; Didanosine; Drug Therapy, Combination; HIV-1; Humans; Hydroxyure | 2005 |
Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
Topics: Acute Disease; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Erythr | 2000 |
Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression.
Topics: Adolescent; Adult; Anti-HIV Agents; Case-Control Studies; CD4 Lymphocyte Count; Drug Therapy, Combin | 2001 |
Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression.
Topics: Adolescent; Adult; Anti-HIV Agents; Case-Control Studies; CD4 Lymphocyte Count; Drug Therapy, Combin | 2001 |
Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression.
Topics: Adolescent; Adult; Anti-HIV Agents; Case-Control Studies; CD4 Lymphocyte Count; Drug Therapy, Combin | 2001 |
Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression.
Topics: Adolescent; Adult; Anti-HIV Agents; Case-Control Studies; CD4 Lymphocyte Count; Drug Therapy, Combin | 2001 |
Low risk of pancreatitis in HIV-infected patients on hydroxyurea plus didanosine.
Topics: Anti-HIV Agents; Didanosine; HIV Infections; HIV-1; Humans; Hydroxyurea; Incidence; Pancreatitis; Re | 2001 |
6 other studies available for hydroxyurea and Pancreatitis
| Article | Year |
|---|---|
Acute pancreatitis as a side effect of anagrelide hydrochloride hydrate: a case report.
Topics: Abdominal Pain; Acute Disease; Aged; Aspirin; Drug Substitution; Female; Humans; Hydroxyurea; Janus | 2016 |
Prevention of increased pulmonary vascular permeability after pancreatitis by granulocyte depletion in sheep.
Topics: Acute Disease; Animals; Capillary Permeability; Granulocytes; Hydroxyurea; Lung; Lymphatic System; M | 1982 |
Drug Points: pancreatitis associated with hydroxyurea in combination with didanosine.
Topics: Acute Disease; Adult; Anti-HIV Agents; Didanosine; Drug Combinations; HIV Infections; Humans; Hydrox | 2001 |
Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs.
Topics: Adult; Amylases; Anti-HIV Agents; Didanosine; Female; HIV Infections; HIV-1; Humans; Hydroxyurea; In | 2001 |
Extended warning on Didanosine-related pancreatitis.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Hum | 1999 |
ddI, d4T, Hydroxyurea: new pancreatitis warning.
Topics: Anti-HIV Agents; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; H | 1999 |